Predicting of survival in metastatic melanoma patients under anti-PD-1 monotherapy using genomic mutation and copy number variation
Yu Wang, Wei Tang, Yuanyuan Wang, Xiaoyu Lu, Ling Zhang, Jiaojiao Yang, Shuibing Yang, Jingjin Yang · 2026
Read Predicting of survival in metastatic melanoma patients under anti-PD-1 monotherapy using genomic mutation and copy number variation by Yu Wang, Wei Tang, Yuanyuan Wang, Xiaoyu Lu, Ling Zhang, Jiaojiao Yang, Shuibing Yang, Jingjin Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13350610.txt.
Description
Drugs that block PD-1 have cut deaths from advanced melanoma, yet only a share of patients gain from them. Yu Wang and co-authors set out in their 2026 paper to predict, before treatment, whose survival would be good or poor on PD-1 blockade alone. They built simple scoring charts, called nomograms, from gene mutation and copy number data in two patient cohorts.
Their top chart rests on five genes and split patients into high-risk and low-risk groups with clearly apart survival times. The same split meant nothing in two cohorts who never got the drug, which shows the chart forecasts drug benefit rather than general fate. The charts are free online, and the authors offer them as an aid for doctors choosing treatment for metastatic melanoma.
Catalog record
| CREATOR | Yu Wang, Wei Tang, Yuanyuan Wang, Xiaoyu Lu, Ling Zhang, Jiaojiao Yang, Shuibing Yang, Jingjin Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |